Whereas the aforementioned studies suggest that GFAP appears to be a useful blood-based biomarker of both the presence and initial severity of TBI, limited work has investigated its value in predicting longer-term outcomes such as the psychological conditions that are prevalent in the mTBI population. This evidence concerns the gene GFAP and concussion.